<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14778">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914509</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-16-002</org_study_id>
    <nct_id>NCT02914509</nct_id>
  </id_info>
  <brief_title>Study Evaluating OTX-TP in OAG and OH</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3a Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost
      drug product, placed in the canaliculus of the eyelid in the treatment of subjects with
      open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>OTX-TP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OTX-TP (sustained release travoprost) Intracanalicular Depot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PV (Placebo Vehicle) Intracanalicular Depot</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost</intervention_name>
    <arm_group_label>OTX-TP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vehicle</intervention_name>
    <arm_group_label>PV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or
             greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or
             evidence of traumatic angle recession.

        Exclusion Criteria:

          -  Punctum size smaller than 0.4 mm or greater than 0.9 mm in either eye as measured
             using a standard punctum gauge.

          -  Known or suspected allergy and/or hypersensitivity to Travoprost or any
             prostaglandin, fluorescein, or to any component of the study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deepa Mulani</last_name>
    <phone>7813574000</phone>
    <email>dmulani@ocutx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fichte, Endl &amp; Elmer Eyecare</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Goodnick</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 2, 2016</lastchanged_date>
  <firstreceived_date>September 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
